Clinical Trials

Sponsor: Bristol Myers Squibb

Sponsor Study ID: CA224-098

Study Title: A Phase 3, Randomized, Double blind Study of Adjuvant Immunotherapy with Relatlimab and Nivolumab Fixed dose Combination versus Nivolumab Monotherapy after Complete Resection of Stage III IV Melanoma (RELATIVITY 098)

CTO #: 103487

NCT Number: NCT05002569

Phase: III

Protocol Type: Treatment

Age Group: Adults

Disease Sites: Melanoma, Skin

Study Objectives: The purpose of this study is to assess relatlimab and nivolumab fixed-dose combination (FDC) versus nivolumab alone in participants with completely resected stage III-IV melanoma.



Study Documents    
(MUSC NetID required for document access)